542
Views
7
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials

, , ORCID Icon, &
Pages 151-167 | Received 01 Apr 2022, Accepted 14 Jun 2022, Published online: 23 Jun 2022
 

ABSTRACT

Introduction

Antibody-mediated rejection (ABMR) is a leading cause of kidney allograft failure. Its therapy continues to be challenge, and no treatment has been approved for the market thus far.

Areas covered

In this article, we discuss the pathophysiology and phenotypic presentation of ABMR, the current level of evidence to support the use of available therapeutic strategies, and the emergence of tailored drugs now being evaluated in systematic clinical trials. We searched PubMed, Clinicaltrials.gov and Citeline’s Pharmaprojects for pertinent information on emerging anti-rejection strategies, laying a focus on phase II and III trials.

Expert opinion

Currently, we rely on the use of apheresis for alloantibody depletion and intravenous immunoglobulin (referred to as standard of care), preferentially in early active ABMR. Recent systematic trials have questioned the benefits of using the CD20 antibody rituximab or the proteasome inhibitor bortezomib. However, there are now several promising treatment approaches in the pipeline, which are being trialed in phase II and III studies. These include interleukin-6 antagonism, CD38-targeting antibodies, and selective inhibitors of complement. On the basis of the information that has emerged so far, it seems that innovative treatment strategies for clinical use in ABMR may be available within the next 5–10 years.

Funding

This paper was not funded.

Abbreviations

ABMR, antibody-mediated rejection

ATG, antithymocyte globulin

C1-INH, C1 esterase inhibitor

CyA, cyclosporin A

CYP, cytochrome P450

DGF, delayed graft function

DSA, donor-specific antibody

eGFR, estimated glomerular filtration rate

EMA, European Medicines Agency

FcγRIIIA, Fc-gamma receptor IIIA

FDA, Food and Drug Administration

HLA, human leukocyte antigen

IL-6, interleukin-6

IL-6R, interleukin-6 receptor

IVIG, intravenous immunoglobulin

KDIGO, Kidney Disease: Improving Global Outcomes

NK cell, natural killer cell

SOC, standard of care

Notes

1. In the pdf version, there is some re-formatting of Table 1 necessary: There seems to be (e.g. in the row B cells/Rtuximab) a shift of the lines. In the column Status of development, the text for each study should be in a line (e.g. Phase II (prematurely terminated)), so that the associated trial acronyms, identifiers and citations are correctly affiliated.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,672.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.